Insilico Medicine’s PandaOmics and Scripps Research employ AI platforms to integrate multi‐omics data and systems biology, identifying polypharmacological compounds that extend lifespan in C. elegans and reduce cellular senescence, paving the way for precision anti‐aging treatments.
Key points
- AgeXtend screens over 1.1 billion compounds, identifying geroprotectors targeting mTOR, AMPK, and sirtuins.
- AI‐designed polypharmacological agents by Scripps Research achieve up to 74% C. elegans lifespan extension by modulating inflammation and mitochondrial function.
- Insilico Medicine’s ISM001-055 TNIK inhibitor reduces cellular senescence markers and shows dose‐dependent benefits in Phase II IPF trials.
Why it matters: AI‐driven discovery of multi‐pathway anti‐aging drugs shifts aging treatment from single‐target approaches to integrative precision medicine.
Q&A
- What is a polypharmacological compound?
- How do AI platforms like PandaOmics accelerate drug discovery?
- What are epigenetic clocks and why do they matter?
- What role do digital twins play in longevity research?